Stitch Fix, Inc. (SFIX)
Pre-Market:
| Previous Close | 5.3700 |
| Open | 5.4100 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 2900 |
| Day's Range | 4.7200 - 5.4600 |
| 52 Week Range | 2.6300 - 11.5000 |
| Volume | |
| Avg. Volume | 2,881,521 |
| Market Cap | 531.596M |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5100 |
| Earnings Date | Jun 07, 2023 - Jun 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.45 |
- Motley Fool
Proceed With Caution When Considering These 5 Ultra-Popular Stocks
It's been a rough time in the stock market over the past year and even good companies with lots of long-term potential experienced massive share price sell-offs right alongside not-so-great companies. You wouldn't know Carvana's business is stuck grinding its gears by looking at the company's 72% year-to-date share price rise.
- Simply Wall St.
Stitch Fix (NASDAQ:SFIX) investors are sitting on a loss of 74% if they invested five years ago
It is doubtless a positive to see that the Stitch Fix, Inc. ( NASDAQ:SFIX ) share price has gained some 81% in the last...
- Investing.com
Hedge funds and C-suites: Illumina pops on Icahn news | Pro Recap
Here is your Pro Recap of the biggest news out of hedge funds and company top brass you may have missed in the past week. Illumina (NASDAQ:ILMN) shares rose sharply on word Carl Icahn is preparing to launch a proxy fight there, seeking three board seats, according to the Wall Street Journal. According to Icahn, the biotech company's acquisition of Grail costed shareholders $50 billion and is now costing the company $800 million annually.
